As reported by the National Law Journal, a federal judge in Boston has denied Saad’s requests to stop the ADA’s flagship journal, Diabetes, from publishing expressions of concern about four of Saad’s papers, and to prevent the journal from retracting the studies.
The State University of Campinas University of Campinas and the American Diabetes Association disagree strongly over how to handle disputed images from faculty member Mario Saad, who is suing the ADA to prevent retraction of his papers.
While the State University of Campinas University of Campinas (Unicamp) acknowledges that 2 of Saad’s papers contain “mistakes”, it concluded there was “not an intention in the actions of the authors,” and the mistakes did not have a negative impact on the scientific community. Ultimately: “the studies published have their own strength, are healthy and were not artificially strengthened by the incorrect images.”
In response, however, Saad’s lawsuit says the ADA asked the school to reinvestigate the articles, and refused to accept any papers from Unicamp faculty in any ADA journals until the issues are resolved.
The ADA has issued four expressions of concern in Saad’s research published in its flagship journal, Diabetes. Saad’s lawsuit aims to prevent the journal from retracting those papers, and asks for monetary compensation.
Retraction Watch has obtained a report of the investigation by Unicamp and Saad’s lawsuit. You can read the full lawsuit here, and the investigation report here.
As reported in the Boston Business Journal, Saad’s lawsuit claims that his institution, the State University of Campinas, investigated two articles at the journal’s behest. The American Diabetes Association was unhappy with the results, and asked the school to reopen the investigation, including two additional papers.
Saad is suing to prevent the journal from retracting the papers, in addition to monetary compensation.
Prominent German diabetes researcher Kathrin Maedler has issued corrections on two papers, and told Retraction Watch she is in the process of defending the data on others.
The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had
uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.
A Nature Cell Biology article on insulin regulation has been retracted after scientists noted that the antibodies used in their research were not as specific as they had previously believed.
The notice is clear on the problems with the science, which together “call into question the main conclusions of the paper.” Three of the paper’s five authors were employed at Novartis at the time of publication.
The stories behind several recent inscrutable retraction notices became a bit more clear today when the Office of Research Integrity (ORI) issued findings in cases involving former researchers at the University of Chicago and the University of California, San Francisco.
Diabetologia has retracted a 2011 meeting abstract from a group in Sweden, indicating that the second author has been found guilty of research misconduct — a charge the scientist denies.
The abstract, “Reduced syntaxin-5 in skeletal muscle of patients with type 2 diabetes is linked to increased diacylglycerol, activation of PKCtheta and impaired insulin signalling,” was presented at the annual meeting of the European Association of the Study of Diabetes. The first author was Kurt Højlund, who now is at the University of Southern Denmark. The second author was Pontus Boström, of the Karolinska Institutet.
Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.
Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.
The University of Calgary researcher who told us earlier this year that he “will not be publishing in the world of science in the future” has retracted two papers from Neuroscience.
